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Background
Tumor-infiltrating T cells (TIL) may represent a viable
source of T cells for the biological treatment of patients
with tumors of the central nervous system. We estab-
lished a rapid TIL expansion protocol for patients with
glioblastoma, and tested the recognition of short-term
expanded tumor autologous tumor cell lines defined by
cytokine production from responding T cells.
Material and methods
Glioma tumor tissue was obtained from 15 patients with
glioblastoma, tumor cell lines were established and TIL
could be successfully expanded in 15/15 cases using a
cytokine cocktail IL-2/IL-15/IL-21, OKT-3 and irra-
diated, allogeneic feeder cells. Intracellular Cytokine
Staining (ICS) was used to detect antigen-specific
immune responses. Autologous tumor cells or TAAs
(NY-ESO-1, Survivin and EGFRvIII peptides) were co-
cultured with TILs for 6 hours in the presence of Brefel-
din A as well as in medium (negative control), or PMA
+Ionomycin (positive control). CD3, CD4 and CD8 mar-
kers were combined with either IL-2, IL17, TNFalpha,
IFNgamma production or 41-BB expression. VB family
composition, exhaustion/activation as well as differentia-
tion markers were tested by flow cytometry.
Results
15/15 TIL could be successfully expanded (up to 10e10
cells) using IL-2, IL-15 and IL-21. The majority of TIL
exhibited a mixture of CD4+, CD8+, as well as CD3+
(TCRalpha/beta) CD4-CD8- T cells with an CD45RA-
CCR7+ phenotype. TILs showed low frequencies of
exhaustion markers, i.e. PD-1 (in CD8+ TILs: median:
3.03%, mean: 3.40%, in CD4+ TILs: median: 2.10%,
mean: 7.73%), TIM-3 (in CD8+ TILs: median: 0.30%,
mean: 1.21%, in CD4+ TILs: median: 0.70%, mean:
1.00%), CTLA-4 (in CD8+ TILs: median: 1.47%, mean:
1.73%, in CD4+ TILs: median: 0.04%, mean: 0.07%) and
LAG-3 (in CD8+ TILs: median: 8.87%, mean: 30.00%, in
CD4+ TILs: median: 1.21%, mean: 1.25%). Some TIL
cultures exhibited preferential usage of VB families (i.e
up to 60% VB22 or VB1 in CD4+ or CD8+ TIL). TIL
from individual patients exhibited NY-ESO-1 specificity
up to 2% in CD4 and CD8+ T cells, yet up to 25% IFN
and TNF production directed against autologous tumor
cells, defined by ICS. Whole genome sequencing is cur-
rently performed in gliomas to subsequently test for
subsequent TIL recognition.
Conclusion
TIL from glioma samples can be reliably and success-
fully expanded in IL-2/IL-15 and IL-21, they exhibit a
Th1-cytokine production pattern and recognize autolo-
gous tumor cells ex vivo. Glioma - reactive TIL repre-
sent a viable source the cellular therapy for patients
with glioblastoma and a Phase I safety trial is currently
prepared at Karolinska.
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